Neither hair loss nor weight gain has been reported in clinical trials as side effects of Vyvgart treatment in patients with generalized myasthenia gravis. Patients are advised to speak with their healthcare provider if they experience any unusual symptoms while on the medication.
FAQs
Some generalized myasthenia gravis (gMG) patients may see results as early as two weeks after starting treatment with Vyvgart. The ADAPT+ trial showed that, in adults with gMG, Vyvgart could rapidly improve scores on a patient- and clinician-reported measure of symptom severity within one…
Vyvgart has been reported to have no or a negligible impact on a person’s ability to drive and use machines. Nevertheless, it’s recommended that patients be careful before attempting to drive or use any machines until they know how Vyvgart affects them. Patients prescribed Vyvgart should talk with their healthcare…
There are no clinical data on the use of Vyvgart in pregnant patients. Animal studies found no evidence of a link between the use of Vyvgart and fetal development abnormalities. Patients who are pregnant or are planning to become pregnant should discuss this issue with their healthcare providers.
The U.S. Food and Drug Administration (FDA) approved Vyvgart in December 2021 to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor. The decision marked the first approval of an FcRn blocker in the U.S. and also made Vyvgart the first…
Neither hair loss nor weight gain has been reported in clinical trials as side effects of Ultomiris treatment in patients with generalized myasthenia gravis. Patients are advised to speak with their healthcare provider if they experience any unusual symptoms while on the medication.
Some generalized myasthenia gravis (gMG) patients may see results as early as one week after starting treatment with Ultomiris. The CHAMPION MG trial showed that, in adults with gMG who had never received a complement inhibitor, Ultomiris could rapidly improve scores on different measures of disease severity within one…
Ultomiris has been reported to have no effect or a negligible impact on a person’s ability to drive or use machines. Nevertheless, it’s recommended that patients be careful before attempting to drive or use any machines until they know how Ultomiris affects them. Patients prescribed Ultomiris should talk with their…
There are no clinical data on the use of Ultomiris in pregnant patients. However, a similar compound, an anti-C5 antibody, caused harm to the developing fetus in animal models. Patients who are pregnant or are planning to become pregnant should discuss this issue with their healthcare providers.
The U.S. Food and Drug Administration approved Ultomiris in April 2022 for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor. In addition to gMG, Ultomiris is approved in the U.S. for atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and neuromyelitis optica spectrum…
Recent Posts
- Regaining control over life when MG weighs me down
- New US patient registry to track MG using real-world data
- Standard treatments don’t always work for triple-seronegative MG
- Exercise, breathing training may help ease myasthenia gravis symptoms
- I learn asking for help means choosing not to do everything the hard way